Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSG | P08311 | 2/20 | 0.54 |
| ▸ | PLAU | P00749 | 2/20 | 0.52 |
| ▸ | MC4R | P32245 | 10/20 | 0.50 |
| ▸ | MC5R | P33032 | 10/20 | 0.50 |
| ▸ | MC3R | P41968 | 10/20 | 0.50 |
| ▸ | MC1R | Q01726 | 10/20 | 0.50 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.49 |
| ▸ | ITGB1 | P05556 | 1/20 | 0.49 |
| ▸ | ITGAV | P06756 | 1/20 | 0.49 |
| ▸ | ITGA5 | P08648 | 1/20 | 0.49 |
| ▸ | ITGB5 | P18084 | 1/20 | 0.49 |
| ▸ | TSLP | Q969D9 | 2/20 | 0.49 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.48 |
| ▸ | ERBB2 | P04626 | 1/20 | 0.47 |
| ▸ | KLKB1 | P03952 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15188725 | 0.82 | ITGB3 (0.59) | CTSGPLAUMC4RMC5RMC3R | |
| SCHEMBL13319649 | 0.82 | CTSG (0.69) | CTSGPLAUTSLPKLKB1 | |
| SCHEMBL18407645 | 0.81 | CTSG (0.49) | CTSGPLAUMC4RMC5RMC3R | |
| SCHEMBL20888358 | 0.79 | ITGB3 (0.58) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL21766911 | 0.79 | ITGB3 (0.58) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL19605458 | 0.79 | ITGB3 (0.58) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL13485740 | 0.79 | MC4R (0.58) | CTSGPLAUMC4RMC5RMC3R | |
| SCHEMBL25474210 | 0.78 | MC4R (0.55) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL19605464 | 0.78 | MC4R (0.55) | MC4RMC5RMC3RMC1RITGB3 | |
| SCHEMBL13485731 | 0.78 | MC4R (0.57) | CTSGPLAUMC4RMC5RMC3R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9487556-B2 | Polyconjugates for delivery of RNAi triggers to tumor cells in vivo | Arrowhead Pharmaceuticals, Inc. (US) | 2016-11-08 | — | — | US | disclosed |
| US-20150045573-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | Arrowhead Pharmaceuticals, Inc. | 2015-02-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150045573-A1 | Polyconjugates for Delivery of RNAi triggers to Tumor Cells In Vivo | PAM, PLAUR, M6PR | CTSG 855/4885PLAU 65/4885MC4R 3035/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.